Literature DB >> 8269630

Tissue protein turnover during liver carcinogenesis.

R A Canuto1, L Tessitore, G Muzio, R Autelli, F M Baccino.   

Abstract

Overall rates of tissue protein degradation in vivo during chemical hepatocarcinogenesis were estimated by a double-isotope method as well as from the accumulation of peptide intermediates in protein degradation induced by bestatin. Several parameters estimating rates of cell proliferation and cell loss have been measured in parallel. The two procedures adopted consistently indicated that protein turnover was significantly slowed down through the whole observation period (12 months after the initiating administration of DENA) in both 'preneoplastic' nodules and hepatomas as compared with control livers or perinodular tissue. Such a difference may confer a selective growth advantage to 'preneoplastic' and tumoral cells. Since protein degradation rates did not appreciably differ between nodules and hepatomas, either such advantage originated from some early step in the carcinogenetic process or it merely reflected the proliferative events in the two cell populations. Yet neither liver nodules nor hepatomas were characterized by very high rates of cell proliferation, however much increased with respect to control liver.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8269630     DOI: 10.1093/carcin/14.12.2581

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  Autophagy in lung cancer.

Authors:  Jerry J Jaboin; Misun Hwang; Bo Lu
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 2.  Autophagic proteolysis: control and specificity.

Authors:  E F Blommaart; J J Luiken; A J Meijer
Journal:  Histochem J       Date:  1997-05

3.  Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro.

Authors:  Xian-Qing Zhang; Xiao-Feng Huang; Xing-Bin Hu; Yong-Hua Zhan; Qun-Xing An; Shi-Ming Yang; Ai-Jun Xia; Jing Yi; Rui Chen; Shi-Jie Mu; Dao-Cheng Wu
Journal:  Asian J Androl       Date:  2010-07-26       Impact factor: 3.285

4.  Evaluation of Apoptotic Marker Bcl2, CD4+, Human Hepatocyte Growth Factor and Metalloproteinase-9 as Tumor Markers for Patients with Hepatocellular Carcinoma.

Authors:  Eman R Youness; Mohamed El Nemr; F S Oraby; Nadia M Ahmed; Mohamed A Moghni; Hanan F Aly; Hanaa H Ahmed
Journal:  Indian J Clin Biochem       Date:  2013-09-08

5.  Immunohistochemical expression of MAP1LC3A and MAP1LC3B protein in breast carcinoma tissues.

Authors:  Ekhlas Qaid Gazem Othman; Gurjeet Kaur; Ahmad Faisal Mutee; Tengku Sifzizul Tengku Muhammad; Mei Lan Tan
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 6.  Programmed cell death pathways and current antitumor targets.

Authors:  Mei Lan Tan; Jer Ping Ooi; Nawfal Ismail; Ahmed Ismail Hassan Moad; Tengku Sifzizul Tengku Muhammad
Journal:  Pharm Res       Date:  2009-04-30       Impact factor: 4.200

Review 7.  Curcumin: updated molecular mechanisms and intervention targets in human lung cancer.

Authors:  Ming-Xiang Ye; Yan Li; Hong Yin; Jian Zhang
Journal:  Int J Mol Sci       Date:  2012-03-22       Impact factor: 6.208

Review 8.  The role of autophagy in hepatocellular carcinoma: friend or foe.

Authors:  Lian Liu; Jia-Zhi Liao; Xing-Xing He; Pei-Yuan Li
Journal:  Oncotarget       Date:  2017-04-18

9.  Tripchlorolide induces autophagy in lung cancer cells by inhibiting the PI3K/AKT/mTOR pathway and improves cisplatin sensitivity in A549/DDP cells.

Authors:  Li-Min Chen; Tian-Jiao Song; Jian-Hong Xiao; Zheng-Hui Huang; Yong Li; Ting-Yan Lin
Journal:  Oncotarget       Date:  2017-07-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.